<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04920799</url>
  </required_header>
  <id_info>
    <org_study_id>IRB202100040</org_study_id>
    <nct_id>NCT04920799</nct_id>
  </id_info>
  <brief_title>Effect of Beet Juice Supplementation on Vascular and Inspiratory Muscle Function</brief_title>
  <official_title>Effect of Beet Juice Supplementation on Vascular and Inspiratory Muscle Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Older adults with coronary artery disease (CAD) have impaired vascular and inspiratory muscle&#xD;
      function. The objective of this study is to examine the effect of beet juice supplementation&#xD;
      on vascular and inspiratory muscle function in older adults with CAD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in endothelial function</measure>
    <time_frame>Baseline up to following 2 weeks of experimental condition</time_frame>
    <description>Endothelial function will be determined using brachial artery flow-mediated dilation via high resolution duplex ultrasonography. Reactive hyperemia will be produced by inflating a forearm cuff to ~250 mmHg for 5 minutes followed by rapid deflation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in inspiratory muscle function</measure>
    <time_frame>Baseline up to following 2 weeks of experimental condition</time_frame>
    <description>Inspiratory muscle function including strength, power and endurance will be assessed using the POWERbreathe KH2 device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in microvascular function</measure>
    <time_frame>Baseline up to following 2 weeks of experimental condition</time_frame>
    <description>Microvascular function will be assessed using the forearm blood flow response to submaximal handgrip exercise. Brachial artery blood flow and diameter will be assessed using ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in central arterial stiffness</measure>
    <time_frame>Baseline up to following 2 weeks of experimental condition</time_frame>
    <description>The SphygmoCor XCEL device will be used to measure carotid to femoral pulse wave velocity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in central arterial hemodynamics</measure>
    <time_frame>Baseline up to following 2 weeks of experimental condition</time_frame>
    <description>The SphygmoCor XCEL device will be used to obtain central pulse wave analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functional capacity</measure>
    <time_frame>Baseline up to following 2 weeks of experimental condition</time_frame>
    <description>Using the Duke Activity Status Index we will assess participants' ability to perform daily activities.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Nitrate rich beetroot juice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitrate depleted beetroot juice</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nitrate rich beetroot juice</intervention_name>
    <description>Participants will drink nitrate rich beetroot juice (2.4 floz ; Beet It Sport Nitrate 400 concentrated beetroot shot; James White Drink, ltd) twice daily for two weeks.</description>
    <arm_group_label>Nitrate rich beetroot juice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nitrate depleted beetroot juice</intervention_name>
    <description>Participants will drink nitrate depleted beetroot juice (2.4 floz ; Beet It placebo concentrated beetroot shot; James White Drink, ltd) twice daily for two weeks.</description>
    <arm_group_label>Nitrate depleted beetroot juice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults with coronary artery disease (CAD) based on an angiogram &gt;50% stenosis in any&#xD;
             major epicardial vessel or history of myocardial infarction or history of coronary&#xD;
             revascularization.&#xD;
&#xD;
          -  Considered to have stable CAD on optimal medical therapy&#xD;
&#xD;
          -  60 to 85 years of age&#xD;
&#xD;
          -  Men and women (women must be postmenopausal either natural or surgical)&#xD;
&#xD;
          -  Able to give consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ejection fraction &lt;50%, unstable angina, recent myocardial infarction within 6 months&#xD;
&#xD;
          -  Coronary revascularization, including percutaneous coronary intervention and coronary&#xD;
             artery bypass graft or thoracic surgery within 6 months.&#xD;
&#xD;
          -  Stroke, obstructive pulmonary disease, hepatitis B, C, HIV, seizures, or other&#xD;
             relevant on-going or recurrent illness&#xD;
&#xD;
          -  Individuals that have participated in respiratory training within the last 12 months&#xD;
             or cardiac rehabilitation within the last 6 months&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Use of tobacco products including smoking traditional or e-cigarettes&#xD;
&#xD;
          -  Use of hormone replacement therapy in women or men (e.g., estrogen, progesterone or&#xD;
             testosterone)&#xD;
&#xD;
          -  Regular aerobic exercise training&#xD;
&#xD;
          -  Unwilling to stop using mouthwash at least 1 week before the start of the study and&#xD;
             during study participation&#xD;
&#xD;
          -  Unwilling to remain weight stable during study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Demetra Christou, PhD</last_name>
    <phone>352-294-1746</phone>
    <email>ddchristou@hhp.ufl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie Lapierre, MS</last_name>
    <email>ICPL@hhp.ufl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Integrative Cardiovascular Physiology Laboratory, University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Demetra Christou, PhD</last_name>
      <phone>352-294-1746</phone>
      <email>ddchristou@ufl.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

